Exelixis | Des Atouts



Assets Changement Date
Acadia Pharmaceuticals USD 1.19B 210.89M 2024-12
Agios Pharmaceuticals USD 1.56B 107.68M 2025-03
Amgen USD 89.37B 2.47B 2025-03
AstraZeneca USD 106.25B 2.22B 2025-03
Bayer EUR 110.85B 3.9B 2024-12
BioMarin Pharmaceutical USD 7.15B 158.07M 2025-03
Bristol-Myers Squibb USD 92.43B 176M 2025-03
Cytokinetics USD 1.26B 137.62M 2025-03
Eisai JPY 1.43T 111.45B 2024-12
Eli Lilly USD 89.39B 10.67B 2025-03
Exelixis USD 2.95B 12.59M 2025-01
Genmab DKK 45.81B 6.15B 2024-12
Glaxosmithkline GBP 59.46B 1.41B 2024-12
Incyte USD 5.75B 305.04M 2025-03
Ionis Pharmaceuticals USD 2.81B 190.73M 2025-03
MacroGenics USD 261.65M 2.84M 2024-12
Merck USD 115.12B 1.98B 2025-03
Moderna USD 12.7B 1.44B 2025-03
Neurocrine Biosciences USD 3.72B 183.7M 2024-12
Novartis USD 102.25B 1.28B 2024-12
Pfizer USD 208.03B 5.37B 2025-03
Sanofi 132.8B 3.04B 2024-12
Takeda JPY 15.11T 533.85B 2024-12
Ultragenyx Pharmaceutical USD 1.31B 191.53M 2025-03
Xencor USD 951.94M 31.69M 2024-12



Exelixis Des Atouts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.